Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.
(2014) In Cancer Biotherapy & Radiopharmaceuticals 29(6). p.238-246- Abstract
- Abstract Alpha-particle emitters, such as astatine-211 ((211)At), are generally considered suitable for the treatment of small cell clusters due to their short path length, while beta-particle emitters, for example, Lutetium-177 ((177)Lu), have a longer path length and are considered better for small, established tumors. A combination of such radionuclides may be successful in regimens of radioimmunotherapy. In this study, rats were treated by sequential administration of first a (177)Lu-labeled antibody, followed by a (211)At-labeled antibody 25 days later. Methods: Rats bearing solid colon carcinoma tumors were treated with 400 MBq/kg body weight (177)Lu-BR96. After 25 days, three groups of animals were given either 5 or 10 MBq/kg body... (More)
- Abstract Alpha-particle emitters, such as astatine-211 ((211)At), are generally considered suitable for the treatment of small cell clusters due to their short path length, while beta-particle emitters, for example, Lutetium-177 ((177)Lu), have a longer path length and are considered better for small, established tumors. A combination of such radionuclides may be successful in regimens of radioimmunotherapy. In this study, rats were treated by sequential administration of first a (177)Lu-labeled antibody, followed by a (211)At-labeled antibody 25 days later. Methods: Rats bearing solid colon carcinoma tumors were treated with 400 MBq/kg body weight (177)Lu-BR96. After 25 days, three groups of animals were given either 5 or 10 MBq/kg body weight of (211)At-BR96 simultaneously with or without a blocking agent reducing halogen uptake in normal tissues. Control animals were not given any (211)At-BR96. Myelotoxicity, body weight, tumor size, and development of metastases were monitored for 120 days. Results: Tumors were undetectable in 90% of the animals on day 25, independent of treatment. Additional treatment with (211)At-labeled antibodies did not reduce the proportion of animals developing metastases. The rats suffered from reversible myelotoxicity after treatment. Conclusions: Sequential administration of (177)Lu-BR96 and (211)At-BR96 resulted in tolerable toxicity providing halogen blocking but did not enhance the therapeutic effect. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4526660
- author
- Eriksson, Sophie LU ; Elgström, Erika LU ; Bäck, Tom ; Ohlsson, Tomas G LU ; Jensen, Holger ; Nilsson, Rune LU ; Lindegren, Sture and Tennvall, Jan LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Biotherapy & Radiopharmaceuticals
- volume
- 29
- issue
- 6
- pages
- 238 - 246
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- pmid:24971673
- wos:000339910500002
- scopus:84904631605
- pmid:24971673
- ISSN
- 1557-8852
- DOI
- 10.1089/cbr.2014.1625
- language
- English
- LU publication?
- yes
- id
- 82848f80-b339-48c7-9bcf-4d3e5bd07fbd (old id 4526660)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24971673?dopt=Abstract
- date added to LUP
- 2016-04-01 10:01:42
- date last changed
- 2022-04-19 22:00:12
@article{82848f80-b339-48c7-9bcf-4d3e5bd07fbd, abstract = {{Abstract Alpha-particle emitters, such as astatine-211 ((211)At), are generally considered suitable for the treatment of small cell clusters due to their short path length, while beta-particle emitters, for example, Lutetium-177 ((177)Lu), have a longer path length and are considered better for small, established tumors. A combination of such radionuclides may be successful in regimens of radioimmunotherapy. In this study, rats were treated by sequential administration of first a (177)Lu-labeled antibody, followed by a (211)At-labeled antibody 25 days later. Methods: Rats bearing solid colon carcinoma tumors were treated with 400 MBq/kg body weight (177)Lu-BR96. After 25 days, three groups of animals were given either 5 or 10 MBq/kg body weight of (211)At-BR96 simultaneously with or without a blocking agent reducing halogen uptake in normal tissues. Control animals were not given any (211)At-BR96. Myelotoxicity, body weight, tumor size, and development of metastases were monitored for 120 days. Results: Tumors were undetectable in 90% of the animals on day 25, independent of treatment. Additional treatment with (211)At-labeled antibodies did not reduce the proportion of animals developing metastases. The rats suffered from reversible myelotoxicity after treatment. Conclusions: Sequential administration of (177)Lu-BR96 and (211)At-BR96 resulted in tolerable toxicity providing halogen blocking but did not enhance the therapeutic effect.}}, author = {{Eriksson, Sophie and Elgström, Erika and Bäck, Tom and Ohlsson, Tomas G and Jensen, Holger and Nilsson, Rune and Lindegren, Sture and Tennvall, Jan}}, issn = {{1557-8852}}, language = {{eng}}, number = {{6}}, pages = {{238--246}}, publisher = {{Mary Ann Liebert, Inc.}}, series = {{Cancer Biotherapy & Radiopharmaceuticals}}, title = {{Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.}}, url = {{http://dx.doi.org/10.1089/cbr.2014.1625}}, doi = {{10.1089/cbr.2014.1625}}, volume = {{29}}, year = {{2014}}, }